Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10636158 | 0.80 | PDK1 (0.33) | ALDH1A1 | |
| SCHEMBL11205239 | 0.80 | NLRP3 (0.44) | ALDH1A1 | |
| SCHEMBL9253076 | 0.74 | — | — | |
| SCHEMBL1202329 | 0.72 | — | — | |
| SCHEMBL4444599 | 0.72 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL25001234 | 0.68 | — | — | |
| SCHEMBL16128855 | 0.67 | — | — | |
| SCHEMBL3700793 | 0.67 | — | — | |
| SCHEMBL12269551 | 0.67 | — | — | |
| SCHEMBL1202326 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247645-B2 | Dihydropyridine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | ALDH1A1 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.